How has AbCellera Biologics Inc.'s non-cash financing activities changed year-over-year?

AbCellera Biologics Inc.'s non-cash financing activities increased by 136.1% year-over-year, from $2.08M to $4.9M.

AbCellera Biologics Inc. ABCL Non-cash financing activities

Revenue$8.3M+96.3%

Operating income-$57.5M+8.2%

Net income-$43.2M+5.4%

EPS (diluted)-$0.14+6.7%

Cash & equivalents$102.1M-44.6%

Total debt$140.2M+107%

Total equity$938.1M-8.3%

Total assets$1.3B-2.8%

Operating cash flow-$33.5M-190%

CapEx$3.8M-64.0%

Free cash flow-$37.4M-68.3%

Market cap$1.84B+59.2%

Enterprise value$1.88B+100.0%

P/S23.3×-26.8×

Operating margin-267.6%-120pp

Net margin-181.7%-77.9pp

FCF margin-238.9%-90.9pp

Return on equity-14.7%-0.8pp

Debt / equity0.1×+0.1×

Current ratio14.1×+3.9×

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept abcl:GovernmentAssistanceNonCashFinancingActivities.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is AbCellera Biologics Inc.'s non-cash financing activities?: AbCellera Biologics Inc. (ABCL) reported non-cash financing activities of $4.9M in Q1 2026.
How has AbCellera Biologics Inc.'s non-cash financing activities changed year-over-year?: AbCellera Biologics Inc.'s non-cash financing activities increased by 136.1% year-over-year, from $2.08M to $4.9M.